Celladon Corp Stock Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Sales 2022 | 13.48 18.42 | Sales 2023 | 15.77 21.55 | Capitalization | 9.96M 13.61M |
---|---|---|---|---|---|
Net income 2022 | -96M -131M | Net income 2023 | -75M -102M | EV / Sales 2022 | -836,796 x |
Net cash position 2022 | 63.29M 86.47M | Net Debt 2023 | 15.36M 20.99M | EV / Sales 2023 | 1,605,487 x |
P/E ratio 2022 |
-0.51
x | P/E ratio 2023 |
-0.13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |